Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCell InstituteTSE:7096 -0.65%69 Days Inventory is 18.39 as of Mar. 2026, which is 7% above its 10-year median of 17.24. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,814.87 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 638 Biotechnology companies, StemCell Institute ranks better than 96.24% on this metric.
The historical rank and industry rank for StemCell Institute's Days Inventory or its related term are showing as below:
TSE:7096'
s Days Inventory Range Over the Past 10 Years
Min: 9.8 Med: 17.24 Max: 19.66
Current: 18.03
During the past 9 years, StemCell Institute's highest Days Inventory was 19.66. The lowest was 9.80. And the median was 17.24.
TSE:7096's Days Inventory is ranked better than 96.24% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs TSE:7096: 18.03
StemCell Institute's Days Inventory
increased
from Mar. 2025 (17.24) to Mar. 2026 (18.39).
It might indicate that StemCell Institute's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
StemCell Institute's Inventory Turnover for the
six
months ended in Mar. 2026 was 9.92.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
StemCell Institute's Inventory-to-Revenue for the
six
months ended in Mar. 2026 was 0.04.
StemCell Institute (TSE:7096) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
StemCell Institute's Inventory Turnover for the
six
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
StemCell Institute's Inventory to Revenue for the
six
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
StemCell Institute Days Inventory Related Terms
StemCell Institute Days Inventory Historical Data
* Premium members only.
The historical data trend for StemCell Institute's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7096 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, StemCell Institute's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's Days Inventory distribution charts can be found below:
* The bar in red indicates where StemCell Institute's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCell Institute (TSE:7096) has a Days Inventory of 18.39 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on StemCell Institute and its competitors. This is near median its historical median of 17.24. Over the past decade, StemCell Institute's Days Inventory has ranged from 9.80 to 19.66. According to the industry distribution chart, StemCell Institute ranks #24 out of 638 companies in the Biotechnology industry, placing it in the top 3.8%.
Is StemCell Institute's Days Inventory too high?
StemCell Institute's current Days Inventory of 18.39 is near median its 10-year median of 17.24. Over the past 10 years, this metric has ranged from a low of 9.80 to a high of 19.66. The Biotechnology industry median Days Inventory is 183.20. StemCell Institute's value of 18.39 is 90% below this industry median. Based on the distribution chart, StemCell Institute ranks #24 out of 638 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #24 out of 638 companies for Days Inventory. This places StemCell Institute in the top 4% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.20. StemCell Institute's value of 18.39 is 90% below this benchmark. Historically, StemCell Institute's own Days Inventory has ranged from 9.80 to 19.66 over the past decade. While the company's 10-year median is 17.24 vs. the industry median of 183.20, StemCell Institute has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StemCell Institute's current Days Inventory of 18.39 is 90% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on StemCell Institute and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCell Institute's current Days Inventory is 18.39, which is near median its own 10-year median of 17.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,814.87, compared to a current price of 円765.00 — trading 57.8% below its estimated fair value. The current Days Inventory is 18.39, which is near median its 10-year median of 17.24 and 90% below the Biotechnology industry median of 183.20. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Days Inventory is 18.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円765.00 is trading 57.8% below its estimated GF Value™ of 円1,814.87.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
Days Inventory: 18.39 (near median its 10-year median of 17.24)
GF Value™: 円1,814.87 vs. price of 円765.00 (57.8% below fair value)
Industry Position: 90% below the Biotechnology median (#24 of 638)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score
Get the complete analysis for TSE:7096
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
